#Japan #Osaka #T2 #Rohto Pharmaceutical #Autonomous Truck

Autonomous Transportation Trials by Rohto Pharmaceutical and T2

In an innovative partnership, Rohto Pharmaceutical Co., based in Osaka, and T2, located in Chiyoda, Tokyo, have announced the initiation of autonomous truck transportation trials. Starting June 29, 2026, these trials aim to transport Rohto's skincare products along a designated segment of the expressways connecting the Kansai and Kanto regions of Japan. This initiative seeks to address ongoing issues within the logistics sector, including labor shortages and long working hours for drivers.

Addressing Logistics Challenges

Rohto Pharmaceutical has been proactive in tackling the challenges faced by the logistics industry. The company has previously implemented strategies to enhance truck loading rates and engaged in collaborative deliveries with other firms. Similarly, T2 aims to launch level 4 autonomous truck operations for trunk transportation by fiscal 2027. Since 2024, T2 has conducted trials using level 2 autonomous trucks across various industries and plans to start regular freight operations in 2025 for companies that complete these trials successfully.

Details of the Trial Implementation

The upcoming autonomous truck trials will utilize level 2 technology to transport Rohto's skincare products. Here are the key details:

• - Duration: The trials will span from June 29, 2026, to December 2026, with a total of four transport runs scheduled.
• - Route: The trucks will operate a round trip (approximately 490 km each way) between Rohto’s logistics base in Ibaraki City (Osaka) and their Kanto logistics base in Sagamihara City (Kanagawa). The test segment, solely using level 2 autonomous driving, will progress primarily along the Meishin Expressway and Tōmei Expressway.
• - Roles: Rohto will manage the selection of logistics bases and the arrangement of trial shipments, while T2 will provide autonomous trucks, collect and analyze driving data, and verify technology performance.
• - Cargo: The shipments will include various skincare-related products.
• - Validation: The trials aim to evaluate the operational effectiveness of autonomous driving integration, as well as the efficiency of designated driving routes and lead times.

Future Prospects and Impact

Upon the completion of these trials, Rohto Pharmaceutical will assess the outcomes to thoroughly evaluate the feasibility of utilizing T2's level 4 autonomous trucks for trunk transportation services. Through this collaboration, the companies aspire to ensure reliable product delivery to their customers while contributing to improved working conditions in logistics and reducing environmental impacts. This initiative aligns with their overarching goal of fostering a more sustainable and well-being-oriented society.

The proactive steps by Rohto and T2 not only represent a significant advancement towards modernizing freight transportation but also serve as a model for other industries grappling with similar logistical challenges.

Conclusion

As Rohto Pharmaceutical and T2 embark on this ambitious journey towards autonomous transportation, the implications for the logistics industry could be profound. By leveraging advanced technologies, these companies exemplify leadership in innovation, sustainability, and the commitment to enhancing customer satisfaction and environmental stewardship within the logistics landscape.